New drug combo targets genetic flaws in tough blood cancers
NCT ID NCT04493138
Summary
This study is testing a combination of two drugs, azacitidine and quizartinib, for adults with advanced forms of blood and bone marrow cancers (like myelodysplastic syndromes). The goal is to find the safest and most effective dose and see if the combination can help control these cancers, especially in patients whose cancers have specific genetic mutations (FLT3 or CBL). The trial is for patients who are newly diagnosed or whose disease has not responded to prior standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.